Is Certara (CERT) overvalued or fairly valued?

MarketChacha shows Certara's valuation in context — a forward P/E of about 16.5, a price-to-book of about 1.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Certara's revenue?

Certara reported revenue of $418.8M for FY2025, with net profit of $-1.6M, per official filings.

What is the share price of Certara (CERT)?

Certara last traded at $6.84 (-0.2% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Certara

CERT · NYSE · Healthcare · United States

$6.84-0.2%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:27 PM

Snapshot

TickerCERT

ExchangeNYSE

SectorHealthcare

IndustryHealth Information Services

CountryUnited States

Employees1,515

HeadquartersRadnor, United States

Market cap$1.1B

P/B1.0

Volume1M

Websitewww.certara.com

Filings tracked6

About Certara

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Profile as reported by Yahoo Finance.

Who owns it

Insiders2.7%
Institutions97.3%
Public & other0.0%

346 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.9.20%
Dimensional Fund Advisors LP5.50%
Deerfield Management Company, L.P5.02%
Jefferies Financial Group Inc.4.41%
Vanguard Portfolio Management LLC3.84%
Vanguard Capital Management LLC3.45%
ArrowMark Colorado Holdings LLC2.95%
Citadel Advisors Llc2.92%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of -0.2% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-15.6% → -0.4%

Margin has expanded by about 15.2 points — the business is getting more profitable.

Return on equity-0.2%

Latest ROE of -0.2% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $96.1M · EPS 0.10

Est. earnings growth -28.9%

Next fiscal year

Rev $405.5M · EPS 0.41

Est. earnings growth +8.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$4.4552-wk range$13.88

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$1.1B

Day change

-0.2%

Fwd P/E

16.5

P/B

1.0

Beta

1.46

Revenue (FY2025)

$418.8M

Net margin

-0.4%

ROE

-0.2%

Revenue CAGR (2y)

+8.7%

EPS (FY2025)

-0.01

Net profit (FY2025)

$-1.6M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about CERT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$418.8M	$-1.6M	-0.01	-0.4%	-0.2%
FY2024	$385.1M	$-12.1M	-0.08	-3.1%	-1.1%
FY2023	$354.3M	$-55.4M	-0.35	-15.6%	-5.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$106.9M	$-8.8M	-0.06	-8.2%
2025Q3	$104.6M	$1.5M	0.01	1.5%
2025Q2	$104.6M	$-2.0M	-0.01	-1.9%
2025Q1	$106.0M	$4.7M	0.03	4.5%
2024Q3	$94.8M	$-1.4M	-0.01	-1.4%
2024Q2	$93.3M	$-12.6M	-0.08	-13.5%
2024Q1	$96.7M	$-4.7M	-0.03	-4.8%
2023Q3	$85.6M	$-49.0M	-0.31	-57.2%
2023Q2	$90.5M	$4.7M	0.03	5.2%
2023Q1	$90.3M	$1.4M	0.01	1.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Exhibits
SEC6/17/2026material
8-K — Shareholder vote results
SEC5/15/2026material
8-K — Results of operations, Other events, Exhibits
SEC5/11/2026material
10-Q filing
SEC5/11/2026
8-K — Material agreement, Exhibits
SEC4/22/2026material
8-K — Executive/director change
SEC3/31/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.